People: Techne Corp (TECH.O)
TECH.O on Nasdaq
67.74USD
17 May 2013
67.74USD
17 May 2013
Price Change (% chg)
$0.24 (+0.36%)
$0.24 (+0.36%)
Prev Close
$67.50
$67.50
Open
$67.65
$67.65
Day's High
$67.98
$67.98
Day's Low
$67.31
$67.31
Volume
68,764
68,764
Avg. Vol
140,374
140,374
52-wk High
$76.02
$76.02
52-wk Low
$62.55
$62.55
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Robert Baumgartner |
56 | 2012 | Chairman of the Board |
Charles Kummeth |
52 | 2013 | Chief Executive Officer, Director |
Roger Lucas |
70 | 1995 | Independent Vice Chairman of the Board |
Gregory Melsen |
60 | 2013 | Chief Financial Officer, Vice President - Finance |
Marcel Veronneau |
58 | 1995 | Vice President - Hematology Operations |
Howard O'Connell |
82 | 2010 | Lead Independent Director |
Charles Dinarello |
69 | 2005 | Independent Director |
John Higgins |
42 | 2009 | Independent Director |
Karen Holbrook |
69 | 2007 | Independent Director |
Roeland Nusse |
62 | 2010 | Independent Director |
Randolph Steer |
62 | 1990 | Independent Director |
Biographies
| Name | Description |
|---|---|
Robert Baumgartner |
Mr. Robert V. Baumgartner, CPA has been appointed as Chairman of the Board of Techne Corp., effective November 2, 2012. Mr. Baumgartner received a bachelor’s degree in business administration from the University of Notre Dame. Mr. Baumgartner has served as Executive Chairman, Chief Executive Officer and Director of the Center for Diagnostic Imaging, Inc., an operator of diagnostic imaging centers, since 2001. Prior to 2001, he held executive positions, including as Chief Executive Officer and Director of American Coating International, President and Chief Executive Officer of First Solar and President of the Apogee Glass Group. He began his professional career at KPMG LLC, an international accounting firm. Mr. Baumgartner serves on the board of Carestream Health, Inc. |
Charles Kummeth |
Mr. Charles R. Kummeth has been appointed as Chief Executive Officer, Director of Techne Corporation effective April 1, 2013. Mr. Kummeth served as President of the Mass Spectrometry and Chromatography Division at Thermo Fisher Scientific Inc. ("Thermo Fisher") from September 2011. From 2009 to September 2011, Mr. Kummeth was President of the Laboratory Consumables Division at Thermo Fisher. At Thermo Fisher Scientific, Mr. Kummeth led a team of thousands of employees to over a billion dollars in annual sales. Prior to joining Thermo Fisher, Mr. Kummeth served in various roles at 3M Corporation, most recently as the Vice President of its Medical Division from 2006 to 2008. Mr. Kummeth serves as a director of Sparton Corporation, an electromechanical device provider, and has since 2011. |
Roger Lucas |
Dr. Roger C. Lucas is an Independent Vice Chairman of the Board of Techne Corporation. He has been Senior Scientific Advisor to the Company’s Board since 1995 and a Director since 1985. He holds a bachelor’s degree in biology from St. Mary’s College in Winona, Minnesota, and a Ph.D. in physiology/biochemistry from the Illinois Institute of Technology. He was a recipient of the National Institutes of Health pre- and post-doctoral fellowships and served as Assistant Professor of Biochemistry at the State University of New York Medical School. Dr. Lucas is a private investor and currently a board member of Envoy Medical Corporation, ChemoCentryx, Inc. and Discovery Genomics, Inc. Dr. Lucas joined R&D Systems in 1980 as Head of Research. In 1985, he founded the Company’s Biotechnology Division. From 1985 until his retirement in 1995, Dr. Lucas was Chief Scientific Officer, Executive Vice President and Secretary of the Company. |
Gregory Melsen |
Mr. Gregory J. Melsen is Chief Financial Officer, Vice President - Finance of Techne Corp. He is no longer Interim Chief Executive Officer of the Company effective April 1, 2013. He has served as the Company's Vice President of Finance and Chief Financial Officer since December 2004. In October 2010, he also assumed the role of Treasurer. Prior to 2004, he held various vice president and chief financial officer positions at several publicly traded companies and was employed by a public accounting firm for 19 years, including nine years as an audit partner. |
Marcel Veronneau |
Mr. Marcel Veronneau is Vice President - Hematology Operations of Techne Corporation., since March 1995. Prior thereto, he served as Director of Operations for R&D Systems’ Hematology Division since joining the Company in 1993. |
Howard O'Connell |
Mr. Howard V. O'Connell is Lead Independent Director of Techne Corporation. Mr. O’Connell has served on the Company’s Board since 1985 and as Lead Independent Director since 2010. Mr. O’Connell has been a private investor since 1990. From 1969 to 1990, he served as Chairman, President and Treasurer of John G. Kinnard and Company, Incorporated, a securities broker-dealer. |
Charles Dinarello |
Dr. Charles A. Dinarello is an Independent Director of Techne Corporation, since 2005. Dr. Dinarello received his medical degree from Yale University and his clinical training at the Massachusetts General Hospital. Since 1996, Dr. Dinarello has been a Professor of Medicine and Immunology at the University of Colorado School of Medicine in Aurora, Colorado. Previously, he was Professor of Medicine and Pediatrics at Tufts University School of Medicine and a staff physician at the New England Medical Center Hospital in Boston. From March 2009 to February 2011, Dr. Dinarello served as acting CEO of Omni Bio Pharmaceutical, Inc. In 1998, Dr. Dinarello was elected to the United States National Academy of Sciences. Dr. Dinarello is considered one of the founding fathers of cytokine biology, and regularly speaks at symposia around the world. For his research in the field, Dr. Dinarello has won numerous awards: the Novartis Prize in Immunology (2010), the Paul Ehrlich Prize (2010), the Bonsfils-Staton Award (2010), the Royal Swedish Academy of Sciences Crafoord Prize in Polyarthritis (2009) and the Albany Medical Center Prize in Medical and Biomedical Research (the U.S. prize in medicine) (2009). Within the past five years, Dr. Dinarello has served as a director of Omni Bio Pharmaceutical, Inc. |
John Higgins |
Mr. John L. Higgins is an Independent Director of Techne Corporation, since 2009. He graduated Magna Cum Laude with a bachelor’s degree from Colgate University. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand’s Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. He is a Director of BioCryst and served as Chairperson of its Audit Committee from January 2011 to March 2012. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies. |
Karen Holbrook |
Dr. Karen A. Holbrook is an Independent Director of Techne Corporation, since 2007. Dr. Holbrook earned bachelor’s and master’s degrees in zoology from the University of Wisconsin-Madison. She earned a Ph.D. in biological structure from the University of Washington School of Medicine, where she pursued postdoctoral training in the Department of Medicine, Division of Dermatology. Dr. Holbrook has served as Vice President for Research and Innovation, University of South Florida, since 2007. She served as President of The Ohio State University from 2002 to 2007. Dr. Holbrook served as Senior Vice President for Academic Affairs and Provost at The University of Georgia, as well as Professor of Cell Biology and Adjunct Professor of Anatomy and Cell Biology and Medicine at the Medical College of Georgia. Before that, Dr. Holbrook served at the University of Florida at Gainesville as Vice President for Research and Dean of the Graduate School, as well as Professor of Anatomy and Cell Biology and Medicine (Dermatology). Her earlier academic career was spent as a Professor of Biological Structure and Medicine at the University of Washington School of Medicine where she gained a national reputation for experience in human fetal skin development and genetic skin disease and was a National Institutes of Health (NIH) Merit awardee. She served as Associate Dean for Scientific Affairs. |
Roeland Nusse |
Dr. Roeland Nusse is an Independent Director of Techne Corporation, since May 2010. Dr. Nusse earned a bachelor’s degree in biology from the University of Amsterdam and a doctorate in molecular biology from the Netherlands Cancer Institute in 1980. He did his postdoctoral fellowship at the University of California, San Francisco. Dr. Nusse has served as Chairman of the Department of Developmental Biology at Stanford University since 2007. Dr. Nusse has been a professor or associate professor in the Department of Developmental Biology at Stanford University and an investigator at the Howard Hughes Medical Institute since 1990. He has also been the chair of the Department of Developmental Biology at Stanford since 2007. Dr. Nusse was previously at the Netherlands Cancer Institute (Amsterdam, The Netherlands) as a staff scientist and ultimately head of the Department of Molecular Biology. Dr. Nusse was elected to the United States National Academy of Sciences in April 2010. Dr. Nusse was previously named a member of the European Molecular Biology Organization in 1988, a member of the Royal Dutch Academy of Sciences in 1997 and a member of the American Academy of Arts and Sciences in 2001. |
Randolph Steer |
Dr. Randolph C. Steer is an Independent Director of Techne Corporation, since 1990. Dr. Steer received his undergraduate degree in physiology and Ph.D. in pathobiology from the University of Minnesota and his medical degree from the Mayo Medical School. Dr. Steer is an independent biotechnology consultant. He served as President and Chief Operating Officer of Capstone Therapeutics Corp. from April 2006 to October 2011. Dr. Steer was elected to the Mayo Clinic Board of Trustees in November 2011. In the past five years, Dr. Steer served as a director of BioCryst Pharmaceuticals, Inc. and Vital Therapies, Inc. Dr. Steer was a consultant to the pharmaceutical and biotechnology industries from 1989 to 2006, where he advised companies in business development, medical marketing and regulatory and clinical affairs. His prior experience includes service as Associate Director of Medical Affairs at Marion Laboratories and as Medical Director at Ciba Consumer Pharmaceuticals. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Robert Baumgartner |
-- |
Charles Kummeth |
-- |
Roger Lucas |
-- |
Gregory Melsen |
362,243 |
Marcel Veronneau |
504,573 |
Howard O'Connell |
-- |
Charles Dinarello |
-- |
John Higgins |
-- |
Karen Holbrook |
-- |
Roeland Nusse |
-- |
Randolph Steer |
-- |
As Of 29 Jun 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Robert Baumgartner |
0 | 0 |
Charles Kummeth |
0 | 0 |
Roger Lucas |
0 | 0 |
Gregory Melsen |
25,426 | 284,750 |
Marcel Veronneau |
39,696 | 703,442 |
Howard O'Connell |
0 | 0 |
Charles Dinarello |
0 | 0 |
John Higgins |
0 | 0 |
Karen Holbrook |
0 | 0 |
Roeland Nusse |
0 | 0 |
Randolph Steer |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
O CONNELL HOWARD V |
2,361 | $65.00 |
KUMMETH CHARLES R |
15,000 | $0.00 |
MELSEN GREGORY J |
1,012 | $49.43 |
O CONNELL HOWARD V |
20,000 | $71.65 |
O CONNELL HOWARD V |
5,000 | $37.10 |
O CONNELL HOWARD V |
8,000 | $71.81 |
VERONNEAU MARCEL |
475 | $67.57 |
VERONNEAU MARCEL |
475 | $51.60 |
MELSEN GREGORY J |
426 | $51.60 |
O CONNELL HOWARD V |
350 | $66.52 |
OLAND THOMAS E |
2,000 | $67.49 |
O CONNELL HOWARD V |
30,000 | $65.02 |
BAUMGARTNER ROBERT V |
1,000 | $62.61 |
VERONNEAU MARCEL |
505 | $81.20 |
VERONNEAU MARCEL |
505 | $40.47 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
